Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

77.500
-3.550-4.38%
Volume:14.66M
Turnover:1.14B
Market Cap:134.46B
PE:-1.29K
High:79.650
Open:78.600
Low:75.900
Close:81.050
52wk High:109.100
52wk Low:36.600
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:1.54
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.060
ROE:8.43%
ROA:2.65%
PB:8.20
PE(LYR):-1,291.67
PS:10.35

Loading ...

JPMorgan Increases Stake in Innovent Bio by 585,900 Shares at HK$79.23 Each

Stock News
·
Feb 12

Innovent Biologics Forges Seventh Partnership with Eli Lilly in $8.85 Billion Deal

Deep News
·
Feb 10

Innovent Appears on Track to Meet 2027 Revenue Target -- Market Talk

Dow Jones
·
Feb 10

INNOVENT BIO Shares Climb Over 5% Again Following Seventh Global Partnership with Eli Lilly; Goldman Sachs Sees Undervaluation

Stock News
·
Feb 10

Asian Market Stocks Trading Below Estimated Value In February 2026

Simply Wall St.
·
Feb 10

Hong Kong Stocks Rebound Strongly During Window Period as New AI Models Provide Positive Boost

Stock News
·
Feb 09

Innovent, Pop Mart Lead Hang Seng Index Higher -- Market Talk

Dow Jones
·
Feb 09

Bank of America Securities Reaffirms "Buy" Rating on Innovent Biologics with HK$113.5 Target Price

Stock News
·
Feb 09

CICC Maintains Outperform Rating on Innovent Biologics with HK$118.3 Target Price

Stock News
·
Feb 09

INNOVENT BIO Shares Surge Over 4% on Strategic Collaboration with Eli Lilly Potentially Worth $8.85 Billion

Stock News
·
Feb 09

INNOVENT BIO and Eli Lilly Form Global Strategic Alliance to Advance Oncology and Immunology Drug Development

Stock News
·
Feb 08

Innovent (1801) Announces Seventh Collaboration with Lilly to Develop Global Oncology and Immunology Medicines

Bulletin Express
·
Feb 08

Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology

Reuters
·
Feb 08

Innovent Biologics and Eli Lilly Announce Global Oncology and Immunology Collaboration

Reuters
·
Feb 08

Innovent Announces Strategic Collaboration With Lilly to Develop New Medicines Globally in Oncology and Immunology

THOMSON REUTERS
·
Feb 08

Innovent Biologics: Is Eligible to Receive Development, Regulatory & Commercial Milestone Payments up to Est $8.5 Bln Contingen Certain Future Events

THOMSON REUTERS
·
Feb 08

Innovent Biologics - Innovent Will Receive a $350 Mln Upfront Payment

THOMSON REUTERS
·
Feb 08

JPMorgan Boosts Stake in Innovent Bio by Approximately 1.23 Million Shares at HK$78.70 Each

Stock News
·
Feb 06

Goldman Sachs Raises INNOVENT BIO's Profit Forecasts, Maintains Buy Rating with HK$102.85 Target

Stock News
·
Feb 06

Innovent Biologics (01801) Announces Monthly Return on Movements in Securities for January 2026

Bulletin Express
·
Feb 05